Conjugation of amiodarone to a novel cardiomyocyte cell penetrating peptide for potential targeted delivery to the heart
Frontiers in Chemistry · 12.07.2023 · 11
DOI: 10.3389/fchem.2023.1220573 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Chemistry, online erschienen am 12.07.2023. Verfasst von Ray Yurko und 4 weiteren Autor:innen. Beteiligte Einrichtung: Peptide Synthesis Facility, University of Pittsburgh, Pittsburgh, PA, United States. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Modern medicine has developed a myriad of therapeutic drugs against a wide range of human diseases leading to increased life expectancy and better quality of life for millions of people. Despite the undeniable benefit of medical advancements in pharmaceutical technology, many of the most effective drugs currently in use have serious limitations such as off target side effects resulting in systemic toxicity. New generations of specialized drug constructs will enhance targeted therapeutic efficacy of existing and new drugs leading to safer and more effective treatment options for a variety of human ailments. As one of the most efficient drugs known for the treatment of cardiac arrhythmia, Amiodarone presents the same conundrum of serious systemic side effects associated with long term treatment. In this article we present the synthesis of a next-generation prodrug construct of amiodarone for the purpose of advanced targeting of cardiac arrhythmias by delivering the drug to cardiomyocytes using a novel cardiac targeting peptide, a cardiomyocyte-specific cell penetrating peptide. Our in vivo studies in guinea pigs indicate that cardiac targeting peptide-amiodarone conjugate is able to have similar effects on calcium handling as amiodarone at 1/15th the total molar dose of amiodarone. Further studies are warranted in animal models of atrial fibrillation to show efficacy of this conjugate.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Peptide Synthesis Facility, University of Pittsburgh, Pittsburgh, PA, United States.
- Division of Cardiology, Department of Medicine, Pittsburgh Heart, Lung, Blood, and Vascular Medicine Institute, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, Unite…
- Deptartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, United States.
Förderung
- NHLBI NIH HHS
- National Institutes of Health
Zitieren
APA
Yurko, R., Islam, K., Weber, B., Salama, G., & Zahid, M. (2023). Conjugation of amiodarone to a novel cardiomyocyte cell penetrating peptide for potential targeted delivery to the heart. Frontiers in Chemistry, 11. https://doi.org/10.3389/fchem.2023.1220573
Vancouver
Yurko R, Islam K, Weber B, Salama G, Zahid M. Conjugation of amiodarone to a novel cardiomyocyte cell penetrating peptide for potential targeted delivery to the heart. Frontiers in Chemistry. 2023;11. doi:10.3389/fchem.2023.1220573
BibTeX
@article{Yurko2023,
author = {Yurko, Ray and Islam, Kazi and Weber, Beth and Salama, Guy and Zahid, Maliha},
title = {Conjugation of amiodarone to a novel cardiomyocyte cell penetrating peptide for potential targeted delivery to the heart},
journal = {Frontiers in Chemistry},
year = {2023},
volume = {11},
doi = {10.3389/fchem.2023.1220573}
}
EUVIMED